On October 14, 2025, analysts at Erste Group Bank upgraded their rating for Eli Lilly and Company (NYSE: LLY) from "hold" to "buy". This positive revision comes amid continued strong demand for the company's popular GLP-1 drugs, Mounjaro and Zepbound, which are considered key drivers of top-line growth. The upgrade follows other recent analyst actions, including a price objective boost by Guggenheim earlier in October, although some firms have adjusted their price targets or ratings in previous months. While the company's official press release feed did not feature any major announcements on this date, the analyst upgrade was the primary news event. There was no specific market reaction analysis available in the provided information.